# Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

> **NCT02991651** · PHASE1 · TERMINATED · sponsor: **Io Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** IRX4204
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT02991651
- **Lead sponsor:** Io Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-07
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** Study drug supply expired. No replacement manufactured. Sponsor did not want to continue study.
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991651, "Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02991651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*